Check Eli Lillys Trial Portal Since Eli Lilly develops retatrutide, their clinical trials website provides another valuable resource
After taking individual risk factors into account, the risk for non-live birth was 29.7% with medication continuation versus 27.1% with non-continuation, a difference that was not deemed statistically significant
To view a copy of this licence, visit About this article Cite this article Tsai, YF., Chen, CH., Wu, YM
Not every patient requires the maximum dose to achieve meaningful results
Novo Nordisk also has rights to expand TransCon-based metabolic products into other therapeutic areas
In fact, its right up there with cholesterol-lowering statin drugs, which have an absolute risk reduction in the same 1.5 percent ballpark